Neuraxis vs Vivani Medical
NRXS and VANI side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NRXS and VANI compare
Vivani Medical is the larger company, worth 1.5 times as much as Neuraxis ($92.0M against $60.3M).
Vivani Medical scores higher on the StockData Score (5 against 0 for Neuraxis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NRXS | VANI |
|---|---|---|
| Size and price | ||
| Market cap | $60.3M | $92.0M |
| Share price | $4.80 | $1.02 |
| Change, 1 year | 104% | −24.7% |
| Change, 5 years | – | −83.7% |
| Beta (5Y) | 0.62 | 2.03 |
| Employees | 24 | 36 |
| StockData Score | ||
| Total score | 0 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 4.9× |
| FCF yield | – | −28.8% |
| Profitability | ||
| Return on equity | – | −220% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | – | 3.25 |
| Altman Z-score | – | −4.73 |
| Piotroski F-score | – | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 21.7% | 5.8% |
| Held by insiders | 39.9% | 53.5% |
| Insider net buying, 12 months | $1.4M | $16.7M (better) |
| Short interest, % of float | 6.0% | 0.88% |
Go deeper
- NRXS stock overview
- NRXS income statement
- NRXS valuation and score
- VANI stock overview
- VANI income statement
- VANI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.